Recent News & Research

*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to be given in combo with JNJ-372 drug or separately and is/or…

*September 2019*  by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we're going to treat patients with EGFR-mutated cancers. At the American Society of Clinical Oncology…

*June 2019*  by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is once a patient develops resistance to an EGFR TKI. Two abstracts…

*October 2019*  by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding options for those with progressive disease, explained Timothy F. Burns, MD,…

*October 2018*  by Shalmali Pal Medpage Today and ASCO   Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early 2018 when it was named the "Advance of the Year" in the ASCO Annual Report. Versions of CAR-T cell therapy have shown promise for extending survival in previously incurable forms…

*August 2019*  Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often occurs. Here, we have observed that hypofractionated EGFR TKI treatment (HypoTKI)…

*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect.  Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival. Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These characteristics—which include not only the particular type of…

BiTE antibodies are showing promise as a potential new treatment option for those of us that have progressed on standard of care treatment. What exactly is a BiTE antibody? BiTE is short for "bi-specific T-cell engager," a class of artificial bi-specific monoclonal antibodies that are being investigated for use as…